CO2022011254A2 - Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática - Google Patents
Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmáticaInfo
- Publication number
- CO2022011254A2 CO2022011254A2 CONC2022/0011254A CO2022011254A CO2022011254A2 CO 2022011254 A2 CO2022011254 A2 CO 2022011254A2 CO 2022011254 A CO2022011254 A CO 2022011254A CO 2022011254 A2 CO2022011254 A2 CO 2022011254A2
- Authority
- CO
- Colombia
- Prior art keywords
- plasma kallikrein
- inhibitors
- carboxamide derivatives
- heteroaromatic carboxamide
- heteroaromatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Carboxamidas heteroaromáticas de la Fórmula (I), en donde Y, R, y Ar son como se definen en la descripción y las reivindicaciones, y sales aceptables desde el punto de vista farmacéutico de estos se pueden usar en los métodos para el tratamiento de enfermedades que pueden verse influenciadas por la inhibición de la calicreína plasmática.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157259 | 2020-02-13 | ||
| PCT/EP2021/053286 WO2021160718A1 (en) | 2020-02-13 | 2021-02-11 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022011254A2 true CO2022011254A2 (es) | 2022-08-19 |
Family
ID=69591572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0011254A CO2022011254A2 (es) | 2020-02-13 | 2022-08-10 | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11760745B2 (es) |
| EP (1) | EP4103562A1 (es) |
| JP (2) | JP7230277B2 (es) |
| KR (1) | KR20220141333A (es) |
| CN (2) | CN115052873A (es) |
| AR (1) | AR121341A1 (es) |
| AU (1) | AU2021218952A1 (es) |
| BR (1) | BR112022013979A2 (es) |
| CA (1) | CA3168690A1 (es) |
| CL (2) | CL2022002101A1 (es) |
| CO (1) | CO2022011254A2 (es) |
| CR (1) | CR20220382A (es) |
| DO (2) | DOP2022000157A (es) |
| EC (1) | ECSP22062410A (es) |
| IL (1) | IL295125A (es) |
| JO (1) | JOP20220186A1 (es) |
| MX (1) | MX2022009941A (es) |
| PE (2) | PE20221591A1 (es) |
| TW (1) | TW202144330A (es) |
| WO (1) | WO2021160718A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| JP2005089362A (ja) | 2003-09-17 | 2005-04-07 | Sumitomo Chemical Co Ltd | アリールピラゾリン化合物及びその用途 |
| US8658685B2 (en) | 2008-01-31 | 2014-02-25 | Activesite Pharmaceuticals, Inc. | Methods for treatment of kallikrein-related disorders |
| EP2807157A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| HUE057851T2 (hu) | 2013-05-23 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma-kallikrein inhibitorai |
| JP6855477B2 (ja) | 2015-10-27 | 2021-04-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
| JP6917988B2 (ja) | 2015-10-27 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
| EP3464271B1 (en) | 2016-05-31 | 2020-05-13 | Kalvista Pharmaceuticals Limited | Pyrazole derivatives as plasma kallikrein inhibitors |
| EP3481391A4 (en) | 2016-07-11 | 2020-03-11 | Lifesci Pharmaceuticals, Inc. | THERAPEUTIC INHIBITOR COMPOUNDS |
| CN110546146B (zh) | 2017-04-21 | 2023-02-21 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的杂芳基羧酰胺衍生物 |
| WO2020035540A1 (en) | 2018-08-16 | 2020-02-20 | Boehringer Ingelheim International Gmbh | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
-
2021
- 2021-02-09 TW TW110104875A patent/TW202144330A/zh unknown
- 2021-02-11 WO PCT/EP2021/053286 patent/WO2021160718A1/en active Application Filing
- 2021-02-11 IL IL295125A patent/IL295125A/en unknown
- 2021-02-11 EP EP21706489.8A patent/EP4103562A1/en active Pending
- 2021-02-11 CN CN202180011395.3A patent/CN115052873A/zh active Pending
- 2021-02-11 KR KR1020227031639A patent/KR20220141333A/ko unknown
- 2021-02-11 US US17/173,213 patent/US11760745B2/en active Active
- 2021-02-11 JO JOP/2022/0186A patent/JOP20220186A1/ar unknown
- 2021-02-11 CA CA3168690A patent/CA3168690A1/en active Pending
- 2021-02-11 CN CN202310088017.6A patent/CN116120287A/zh active Pending
- 2021-02-11 AU AU2021218952A patent/AU2021218952A1/en active Pending
- 2021-02-11 MX MX2022009941A patent/MX2022009941A/es unknown
- 2021-02-11 PE PE2022001696A patent/PE20221591A1/es unknown
- 2021-02-11 JP JP2022514811A patent/JP7230277B2/ja active Active
- 2021-02-11 BR BR112022013979A patent/BR112022013979A2/pt unknown
- 2021-02-11 PE PE2023001617A patent/PE20231985A1/es unknown
- 2021-02-11 CR CR20220382A patent/CR20220382A/es unknown
- 2021-02-12 AR ARP210100385A patent/AR121341A1/es unknown
-
2022
- 2022-08-03 DO DO2022000157A patent/DOP2022000157A/es unknown
- 2022-08-04 CL CL2022002101A patent/CL2022002101A1/es unknown
- 2022-08-10 CO CONC2022/0011254A patent/CO2022011254A2/es unknown
- 2022-08-10 EC ECSENADI202262410A patent/ECSP22062410A/es unknown
-
2023
- 2023-02-15 JP JP2023021625A patent/JP2023067881A/ja active Pending
- 2023-04-28 CL CL2023001244A patent/CL2023001244A1/es unknown
- 2023-08-25 US US18/455,865 patent/US20240002363A1/en active Pending
- 2023-09-14 DO DO2023000195A patent/DOP2023000195A/es unknown
- 2023-09-18 US US18/468,885 patent/US20240076286A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021160718A1 (en) | 2021-08-19 |
| JP2022543494A (ja) | 2022-10-12 |
| DOP2022000157A (es) | 2022-09-15 |
| TW202144330A (zh) | 2021-12-01 |
| CN115052873A (zh) | 2022-09-13 |
| ECSP22062410A (es) | 2022-09-30 |
| JP7230277B2 (ja) | 2023-02-28 |
| CN116120287A (zh) | 2023-05-16 |
| US20240002363A1 (en) | 2024-01-04 |
| PE20231985A1 (es) | 2023-12-12 |
| CA3168690A1 (en) | 2021-08-19 |
| PE20221591A1 (es) | 2022-10-10 |
| IL295125A (en) | 2022-09-01 |
| US20210292301A1 (en) | 2021-09-23 |
| JOP20220186A1 (ar) | 2023-01-30 |
| MX2022009941A (es) | 2022-09-12 |
| CL2023001244A1 (es) | 2023-11-03 |
| US11760745B2 (en) | 2023-09-19 |
| JP2023067881A (ja) | 2023-05-16 |
| AR121341A1 (es) | 2022-05-11 |
| CR20220382A (es) | 2022-09-16 |
| BR112022013979A2 (pt) | 2022-10-11 |
| CL2022002101A1 (es) | 2023-01-27 |
| EP4103562A1 (en) | 2022-12-21 |
| US20240076286A1 (en) | 2024-03-07 |
| KR20220141333A (ko) | 2022-10-19 |
| AU2021218952A1 (en) | 2022-07-28 |
| DOP2023000195A (es) | 2023-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000038A (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| UY35971A (es) | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| DOP2023000195A (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| CL2021001461A1 (es) | Moduladores de trex1 | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| PA8821301A1 (es) | Inhibidores a base de hidroxamato de desacetilasas b | |
| BR112022021381A2 (pt) | Compostos para o tratamento de sars | |
| CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CO2022010878A2 (es) | Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a | |
| CO2018004572A2 (es) | Inhibidores de calicreína plasmática humana | |
| UY38665A (es) | Agentes antiproliferativos para el tratamiento de pah | |
| CR20220199A (es) | Inhibidores del factor d del complemento para administración oral | |
| CO2021008535A2 (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
| AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| DOP2011000053A (es) | Agentes antifungicos | |
| AR121340A1 (es) | Derivados de carboxamida heteroaromáticos como inhibidores de calicreína plasmática | |
| ECSP23088732A (es) | Moduladores de trex1 | |
| EA201990109A1 (ru) | Митохондриальные ингибиторы для лечения пролиферативных нарушений | |
| BR112022003768A2 (pt) | Compostos inibidores de perk |